Audited Standalone and Consolidated Financial Results for the quarter and year ended on 31st March, 2026
3BBLACKBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
3B BlackBio Dx Ltd (formerly Kilpest India) reported strong FY26 results. Standalone revenue grew 7.5% to Rs 972.75 crore, while consolidated revenue surged 47.1% to Rs 1419.18 crore, boosted by the acquisition of Coris Bioconcept SRL, Belgium. Consolidated PAT grew 25.7% to Rs 599.29 crore, meeting the 25% growth threshold. The board recommended a 50% dividend (Rs 5 per share). Auditors Baheti & Co issued unmodified opinions on both standalone and consolidated results. One-time M&A advisory fees of Rs 174.08 lakh were incurred for the Coris acquisition. Other income declined due to lower NAV of debt mutual funds. The company operates in two segments: Agrochemicals and Molecular Diagnostic Kits, with diagnostics now being the dominant revenue contributor at Rs 131.12 crore in FY26.
The 47% consolidated revenue growth driven by the Coris acquisition and 25.7% PAT growth are positive signals. Shareholders can expect reward from the dividend declaration. The clean audit with unmodified opinion indicates financial health with no going concern issues.